The content on this site is intended for healthcare professionals only
Dr Grande talks to ecancertv at ASCO 2014 about his work looking at regorafenib as a single agent for first-line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer. The work is ongoing but has indicated that the drug is safe and potentially beneficial in those who are too frail to undergo chemotherapy.
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC
The Southeast Asian Breast Cancer Symposium; background, aims and successes
OncoAlert Round Up for August 4th - 10th, 2023
Management of prostate cancer in Africa: Looking to the future
The current status of multiple myeloma diagnosis and treatment
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours
Hypofractionated high dose intensity modulated radiotherapy non-inferior for prostate cancer
